[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-in-remission\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-in-remission":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100516609","phase-1-universal-car-t-cells-targeting-multiple-myeloma-100516609",false,"NCT06006741","Universal CAR-T Cells Targeting Multiple Myeloma","Universal CAR-T Cells for the Treatment of Multiple Myeloma","Inclusion Criteria:\n\n1. Patients with confirmed multiple myeloma failed curative treatment options (including autologous or allogeneic SCT).\n2. Complete remission (CR) cannot be achieved after at least 2 prior therapy regimens.\n3. High risk MM in CR1 or CR2 and not eligible for SCT because of age or comorbid diseases.\n4. Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval \\\u003C 1 year).\n5. Relapsed after prior autologous or allogenic SCT with residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.\n6. Residual disease after primary therapy and not eligible for ASCT\n7. Expected survival \\> 12 weeks• Creatinine \\\u003C 2.5 mg\u002Fdl• ALT (alanine aminotransferase)\u002FAST (aspartate aminotransferase) \\\u003C 3x normal\n8. Bilirubin \\\u003C 2.0 mg\u002Fdl\n9. Any relapse after prior SCT is eligible regardless of other prior therapy\n10. Adequate venous access for apheresis, and no other contraindications for leukapheresis\n11. Voluntary informed consent is signed\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Uncontrolled active infection\n3. Active hepatitis B or hepatitis C infection\n4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.\n5. Previous related CAR-T cell therapy\n6. Any uncontrolled active medical disorder that would preclude participation\n7. HIV infection","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.",[27],"Multiple Myeloma in Remission",[29,30],"Universal CART","multiple myelomachimeric antigen BCMA CD38 CD56 CD138 CD19","RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":35},"2023-10-31",{"date":39,"type":21},"2026-12-31",{"name":41,"class":42},"Shenzhen Geno-Immune Medical Institute","OTHER"]